Report Overview

The treatment dynamics report meets the needs of life sciences companies with inline or pipeline therapies or diagnostics in the HR+ HER2- breast cancer space (early and metastatic). The clinical data is from over 1,100 patient across over 630 hospitals. It includes both total and recently diagnosed cohorts and is representative of the US market.

• For companies needing a new source of data triangulation or those with pipeline therapies/diagnostics, it provides foundational learnings across all aspects of the patient journey, from biomarker testing and results through to treatment usage across all lines of therapy.
• For companies with inline therapies/diagnostics, the treatment data can be applied to understand and forecast market share at the class and brand level and track other key performance indicators over time. 

The report will be issued quarterly and available on a 1-year subscription. It specifically meets the following three goals: 

1. Dives deeply into the HR+/HER2- patient journey, separately for representative cohorts of early (Stage I-III) and metastatic breast cancer patients (US only)
2. Quantifies oncologists’ testing and treatment dynamics, including discontinuation or other disruption with reasons, by line of therapy
3. Integrates clinical data with patient SDOH characteristics and validated patient-reported outcomes (PROs) to create new insight